A phase I/IIa double blind single institute trial of low dose sirolimus for Pendred syndrome/DFNB4

MLA

Kaoru Ogawa, et al. “A Phase I/IIa Double Blind Single Institute Trial of Low Dose Sirolimus for Pendred Syndrome/DFNB4.” Medicine, vol. 99, May 2020, p. e19763. EBSCOhost, https://doi.org/10.1097/md.0000000000019763.

APA

Kaoru Ogawa, Yasuko Saito, Shin-ya Nishio, Masato Fujioka, Keisuke Yoshihama, Makoto Hosoya, Kayoko Kikuchi, Takumi Akiyama, Keita Tsukada, Shin-ichi Usami, Tomonobu Hasegawa, Yuto Fujiki, Tatsuo Matsunaga, Yasunori Sato, & Hiroyuki Ozawa. (2020). A phase I/IIa double blind single institute trial of low dose sirolimus for Pendred syndrome/DFNB4. Medicine, 99, e19763. https://doi.org/10.1097/md.0000000000019763

Chicago

Kaoru Ogawa, Yasuko Saito, Shin-ya Nishio, Masato Fujioka, Keisuke Yoshihama, Makoto Hosoya, Kayoko Kikuchi, et al. 2020. “A Phase I/IIa Double Blind Single Institute Trial of Low Dose Sirolimus for Pendred Syndrome/DFNB4.” Medicine 99 (May): e19763. doi:10.1097/md.0000000000019763.